BRCA1 and ovarian cancer: The BET bromodomain inhibitor JQ1 synergized with the PARP inhibitor olaparib in BRCA1/2 wild-type ovarian cancer both in vitro and in vivo and was correlated with the suppression of both TOPBP1 and WEE1 [19].